甘李药业股份有限公司_公司详情_供应商_CPHI制药在线专业网上贸易平台

制药在线首页

公司概况
成立年份： 1998
总资产(USD)：不愿意公开
员工总人数： 500以上
主要竞争优势：品牌，国际认证/标准，经验丰富的研发人员，生产能力，合同定制，良好的信誉，优质服务
其他竞争优势：
专利与版权： US, EU, Australia, Russia, China, Japan, and Korea: molecular chaperone technology China: Glargine crystallization technology

业务概况
业务类型：制造商，出口商
年销售额(USD)：不愿意公开
主要销售市场：北美洲，中/南美洲，西欧，东欧，亚洲，中东，非洲
主要产品类别：原料药，生物制品，药品制剂
所有产品： 1.Insulin: a. Basalin®(insulin glargine injection) b. Prandilin™(insulin lispro injection) c. Prandilin™25R(insulin lispro 25R injection) d. Rapilin®(insulin aspart injection) e. Rapilin®30(insulin aspart 30 injection) f. Similin®30(insulin human 30 injection) 2.Medical Device: a. GanleePen™(insulin pen) b. GanleeFine®(pen needle)
外销比重：
内销比重：
主要客户：

其它信息
合同定制：
付款条款：

公司详情

Founded in 1998, Gan & Lee Pharmaceuticals is a leading biopharmaceutical company in China specializing in the development, production, and commercialization of insulin analogs and supporting medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters and nearly 3000 employees. With state-of-the-art buildings and GMP facilities, Gan & Lee has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.

里程碑

1998 - Developed China’s first recombinant human insulin

2001 - Developed China's first fast-acting insulin analog (lispro)

2002 - Developed China’s first long-acting insulin analog (glargine) and first premixed insulin analog (lispro 25)

2009 - Developed China’s first insulin pen

2013 - Developed second generation insulin pen

2014 - Founded US subsidiary - Gan & Lee Pharmaceuticals USA

2015 - Initiated phase I clinical trial on insulin glargine in Germany

2017 - Initiated phase III clinical trials on insulin glargine in the USA and EU

2019 - Initiated phase I clinical trials on insulin lispro and aspart in the USA and EU

2020 - Initially listed on the A-share index on the Shanghai Stock Exchange

2021 - Completed phase I clinical trials on insulin glargine in Germany